With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2 House passes bill that extends ACA subsidies through 2025, makes drug price reforms Biotechs face brutal pipeline decisions as industry waits for M&A 'buffet' Boston Scientific bulks up blood-blocking portfolio with Obsidio acquisition Health tech Q2 earnings update—GoodRx resolves grocer spat; Progyny sees strong demand for fertility benefits In needed boon for Gilead, Trodelvy chalks up surprise breast cancer survival win OIG: Part D plans sidestepped cheaper hep C generics for pricey brand-name versions Illumina sets aside $453M to prep for potential EU fines over Grail acquisition GSK turns down one solid tumor collaboration, but Ideaya thinks it’s for the best MRI-reading AI homes in on the brain abnormalities that cause drug-resistant epilepsy A year after FDA slammed on the breaks, BrainStorm is hitting the gas with updated data, approval plans Could voice-analyzing AI improve mental healthcare? Ellipsis and Ceras are banking on it Pyxis puts 2 drugs on backburner and a 3rd on the scrapheap to rally resources behind lead cancer programs AstraZeneca and Daiichi's Enhertu winning streak rolls on with confirmatory trial victory in advanced breast cancer Featured Story | By Kevin Dunleavy Despite a bevy of economic challenges in the second quarter, the biopharmaceutical industry got through the period with solid sales as 15 of the top 24 companies saw a revenue increase over the second quarter of 2021. Pfizer, AstraZeneca and Merck were the top gainers while Regeneron and BioNTech took the largest hits. read more |
| |
|---|
|
Top Stories By Robert King The House passed the Inflation Reduction Act that includes key reforms to drug prices and extends enhanced ACA subsidies, sending the bill to President Biden. read more By Annalee Armstrong We’re seeing a seemingly unprecedented reckoning from biotech C-suites, where executives are making tough calls about continuing to keep the lights on or cutting once-promising candidates. read more By Andrea Park After a whirlwind 2021 that saw Boston Scientific gobbling up a handful of smaller companies left and right, the medtech giant’s M&A appetite seems to have slowed. read more By Heather Landi Digital healthcare platform GoodRx had good news to share during its second-quarter earnings call as it settled a costly spat with a grocery chain's drug store and posted financial results that beat Wall Street forecasts. read more By Angus Liu After Trodelvy failed to impress in staving off tumor progression in HR-positive, HER2-negative breast cancer, Gilead placed a bet on the drug showing a life extension benefit. Now, the drugmaker has surprisingly returned with that win, but industry watchers remain skeptical. read more By Robert King Some Medicare Part D plans did not cover authorized generic versions of pricey hepatitis C drugs, with rebates likely to blame, an OIG report found. read more By Conor Hale The rainy day money for potential legal troubles dragged Illumina's quarterly income into the red, while sales slumped due to global macroeconomic challenges and the company cut back its financial outlook for the year. read more By James Waldron GSK has passed on the chance to go all-in on one of its cancer collaborations with Ideaya Biosciences, but the precision medicine company feels fine about the decision. read more By Andrea Park "This algorithm could help to find more of these hidden lesions in children and adults with epilepsy and enable more patients with epilepsy to be considered for brain surgery that could cure the epilepsy and improve their cognitive development,” Konrad Wagstyl, Ph.D., co-senior author of the study, said in a statement. read more By Max Bayer Almost a year and a half after the FDA spiked phase 3 data of BrainStorm's ALS therapy, the company is asking regulators for approval, pointing to amended figures. The company says that a new analysis of a subset of patients showed statistical significance. read more By Andrea Park Blending Ellipsis’ voice analysis AI into Ceras' connected care platform will allow healthcare providers to monitor real-time changes in their patients’ mental health. read more By Nick Paul Taylor Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs to clinical data drops. read more By Fraiser Kansteiner After an historic HER2-low green light at the beginning of the month—plus yet another approval last week—blockbuster-to-be Enhertu clinched a confirmatory trial win that could see it widen its foothold in the breast cancer market, where Roche and Genentech’s Herceptin and Kadcyla have long reigned supreme. read more Resources Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 